Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152503 · ClinicalTrials.gov registry record · Phase 2
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
A Phase 2 study of Epilepsy, Partial, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 17
- Study locations
NCT00152503 is a Phase 2 study of Epilepsy, Partial that has completed, run by UCB Pharma. The registered enrollment target is 59 participants. The trial reports 17 study locations across 15 states.
The verdict
NCT00152503, a Phase 2 study of Epilepsy, Partial, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 17
- Study locations
Study Summary
This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
Conditions Studied
Interventions
- DRUG Seletracetam (UCB44212)
Study Locations (17)
Ohio
- - Cincinnati
- - Columbus
Other
- - Calgary
- - Montreal
Arizona
- - Phoenix
Arkansas
- - Little Rock
Florida
- - St. Petersburg
Illinois
- - Springfield
Kansas
- - Wichita
Michigan
- - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2005-08-31 |
| Est. Completion | 2006-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00152503
The ClinicalTrials.gov registry entry for NCT00152503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy, Partial appearing as the primary indexed condition, and to 1 intervention - of which Seletracetam (UCB44212) is the first listed.
NCT00152503 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Ohio, Other, Arizona.
Frequently Asked Questions
What is clinical trial NCT00152503 about?
NCT00152503 is a clinical study titled "Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam". This trial will evaluate the efficacy and safety of UCB44212 as add-on therapy in subjects with focal epilepsy.
What is the current status of trial NCT00152503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2005-08-31. Estimated completion is 2006-05-12.
What conditions does trial NCT00152503 study?
This clinical trial studies the following conditions: Epilepsy, Partial.
What interventions are being tested in trial NCT00152503?
The interventions under investigation include: Seletracetam (UCB44212) (DRUG).
Who is sponsoring clinical trial NCT00152503?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00152503 being conducted?
This trial has 17 study locations across Arizona, Arkansas, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.